Skip Navigation
Print This Page
Share this page: More

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis

Application No: NA_00068294

Principal Investigator: Daniel Harrison

For more information please contact Julie Fiol at 410-955-8704

This research is being conducted to determine if natalizumab is effective in slowing disability progression in multiple sclerosis patients with secondary progression.  Natalizumab is a once monthly intravenous infusion that is currently FDA-approved for use in relapsing remitting MS. 

Participants must be between the ages of 18 and 58 and have a diagnosis of secondary progressive MS with evidence of disability progression for more than 2 years independent of relapses.  Participants will be randomized to receive once-monthly infusions of natalizumab or placebo.


Multiple Sclerosis Research

Discover how FOX Sports Supports is helping to raise awareness about autoimmune disease research
Learn more.

Related Links

Experimental Drug Improves Memory in Mice with Multiple Sclerosis

Using The Eye As A ‘Window Into The Brain’

Low Vitamin D Levels Linked to More Severe Multiple Sclerosis Symptoms

Attacking Two Brain Disorders on Multiple Fronts

Learn more about the relationship between multiple sclerosis and transverse myelitis at Project RESTORE.
Project RESTORE team


Looking Forward

Looking Forward

Previous Issues


Out-of-State and International Patients - Find Out More


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer